BOBrian Orcutt-Jahns

Brian Orcutt-Jahns

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brian Orcutt-Jahns has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron Samuel Meyer

    Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90024, USA

    7 shared publications
  • Adina Matache

    Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, USA

    2 shared publications
  • Andrei S. Rodin

    Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, USA

    2 shared publications
  • Peter C. Emmel

    Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA

    2 shared publications
  • Peter P. Lee

    Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, USA

    2 shared publications
  • Russell C. Rockne

    Department of Computational and Quantitative Medicine, Division of Mathematical Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA

    2 shared publications

Latest Publications

  • Open Access

    Linking live-cell behavior to transcriptional responses across perturbations using dynamic caging

    by Brian Orcutt-Jahns, Raúl A. Reyes Hueros, Ana M. Meireles, Christian Cox, Luca Ghita, Jack Kamm, Cemre Celen, Yiming Yang, Eloise Zargari-Pariset, Nirvan Rouzbeh, et al.

    Single-cell technologies, encompassing molecular, morphological, and functional assays, have emerged as cornerstones of modern biological research and discovery. However, current experimental methods often fail to explicitly link these ‘omic’ modalities, especially in live cells or longitudinally through time, impeding the study of multi-scale interactions and mechanisms of regulation. CellCage Enclosure (CCE) technology overcomes these limitations by dynamically compartmentalizing cells, allowing for scalable, live-cell, longitudinal exploration and simultaneous analysis of transcriptomic, proteomic, and morphological profiles. Using this novel technology, we generate previously inaccessible insights across various in vitro cellular systems under a diverse set of perturbations, including the discovery of morphological and proteomic features linked to immune suppressive gene set expression in human primary regulatory T cells (Tregs), as well as direct association of morphological and proteomic features with inflammatory gene modules in human colonic fibroblasts. We then develop a novel pooled CRISPR genetic screening technology using CCEs, PERTURB-LINK (PERTURBational LINKage of transcriptomics and imaging in single cells via enclosure-based screening) and apply this approach in murine bone marrow derived macrophages (BMDMs), enabling multiomic dissection of NF-κB pathway regulation in response to lipopolysaccharide (LPS) stimulation. Together, these findings demonstrate the broad impact that advancements in live-cell, paired multimodal technologies, especially upon perturbation, may offer in deepening our understanding of cellular biology.


  • Open Access

    Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients’ blood

    by Brian Orcutt-Jahns, Joao Rodrigues Lima Junior, Emily Lin, Russell C. Rockne, Adina Matache, Sergio Branciamore, Ethan Hung, Andrei S. Rodin, Peter P. Lee, Aaron S. Meyer

    Cytokines operate in concert to maintain immune homeostasis and coordinate immune responses. In cases of ER+ breast cancer, peripheral immune cells exhibit altered responses to several cytokines, and these alterations are correlated strongly with patient outcomes. To develop a systems-level understanding of this dysregulation, we measured a panel of cytokine responses and receptor abundances in the peripheral blood of healthy controls and ER+ breast cancer patients across immune cell types. Using tensor factorization to model this multidimensional data, we found that breast cancer patients exhibited widespread alterations in response, including drastically reduced response to IL-10 and heightened basal levels of pSmad2/3 and pSTAT4. ER+ patients also featured upregulation of PD-L1, IL6Rα, and IL2Rα, among other receptors. Despite this, alterations in response to cytokines were not explained by changes in receptor abundances. Thus, tensor factorization helped to reveal a coordinated reprogramming of the immune system that was consistent across our cohort.


  • Open Access

    Integrative, high-resolution analysis of single cell gene expression across experimental conditions with PARAFAC2-RISE

    by Andrew Ramirez, Brian T. Orcutt-Jahns, Sean Pascoe, Armaan Abraham, Breanna Remigio, Nathaniel Thomas, Aaron S. Meyer

    Effective tools for exploration and analysis are needed to extract insights from large-scale single-cell measurement data. However, current techniques for handling single-cell studies performed across experimental conditions (e.g., samples, perturbations, or patients) require restrictive assumptions, lack flexibility, or do not adequately deconvolute condition-to-condition variation from cell-to-cell variation. Here, we report that the tensor decomposition method PARAFAC2 (Pf2) enables the dimensionality reduction of single-cell data across conditions. We demonstrate these benefits across two distinct contexts of single-cell RNA-sequencing (scRNA-seq) experiments of peripheral immune cells: pharmacologic drug perturbations and systemic lupus erythematosus (SLE) patient samples. By isolating relevant gene modules across cells and conditions, Pf2 enables straightforward associations of gene variation patterns across specific patients or perturbations while connecting each coordinated change to certain cells without pre-defining cell types. The theoretical grounding of Pf2 suggests a unified framework for many modeling tasks associated with single-cell data. Thus, Pf2 provides an intuitive universal dimensionality reduction approach for multi-sample single-cell studies across diverse biological contexts. Highlights PARAFAC2 enables tensor-based analysis of single-cell experiments across conditions. PARAFAC2 separates condition-specific effects from cell-to-cell variation. PARAFAC2 provides intuitive isolation of patterns into condition-, cell-, and gene-specific patterns.


  • Open Access

    Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients’ blood

    by Brian Orcutt-Jahns, Joao Rodrigues Lima Junior, Russell C. Rockne, Adina Matache, Sergio Branciamore, Ethan Hung, Andrei S. Rodin, Peter P. Lee, Aaron S. Meyer

    Cytokines mediate cell-to-cell communication across the immune system and therefore are critical to immunosurveillance in cancer and other diseases. Several cytokines show dysregulated abundance or signaling responses in breast cancer, associated with the disease and differences in survival and progression. Cytokines operate in a coordinated manner to affect immune surveillance and regulate one another, necessitating a systems approach for a complete picture of this dysregulation. Here, we profiled cytokine signaling responses of peripheral immune cells from breast cancer patients as compared to healthy controls in a multidimensional manner across ligands, cell populations, and responsive pathways. We find alterations in cytokine responsiveness across pathways and cell types that are best defined by integrated signatures across dimensions. Alterations in the abundance of a cytokine’s cognate receptor do not explain differences in responsiveness. Rather, alterations in baseline signaling and receptor abundance suggesting immune cell reprogramming are associated with altered responses. These integrated features suggest a global reprogramming of immune cell communication in breast cancer. Significance Statement: While individual cytokine responses have previously been observed to be altered in breast cancer, cytokine signaling responses are tightly interconnected in a way that has not been previously characterized. Here, we profile cytokine signaling responses and find alterations that are shared across both pathways and cell types. The signatures across these measurements better define the alterations and point to a broad immunosuppression response. Highlights: Baseline and post-stimulation cytokine signaling profiles differ between healthy donors and breast cancer patients. Changes in cytokine response are not explained by differences in abundance of the cognate receptor Features of signaling response and receptor abundance dysregulation are coordinated across patients Integrated patterns of dysregulation in breast cancer patients share features of Th17 like-response as well as regulatory-like B and CD8 + T cells


  • Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells

    by Brian T. Orcutt-Jahns, Peter C. Emmel, Eli M. Snyder, Scott D. Taylor, Aaron S. Meyer

    The cytokine interleukin-2 (IL-2) has the potential to treat autoimmune disease but is limited by its modest specificity toward immunosuppressive regulatory T (T reg ) cells. IL-2 receptors consist of combinations of α, β, and γ chains of variable affinity and cell specificity. Engineering IL-2 to treat autoimmunity has primarily focused on retaining binding to the relatively T reg -selective, high-affinity receptor while reducing binding to the less selective, low-affinity receptor. However, we found that refining the designs to focus on targeting the high-affinity receptor through avidity effects is key to optimizing T reg selectivity. We profiled the dynamics and dose dependency of signaling responses in primary human immune cells induced by engineered fusions composed of either wild-type IL-2 or mutant forms with altered affinity, valency, and fusion to the antibody Fc region for stability. T reg selectivity and signaling response variations were explained by a model of multivalent binding and dimer-enhanced avidity—a combined measure of the strength, number, and conformation of interaction sites—from which we designed tetravalent IL-2–Fc fusions that had greater T reg selectivity in culture than do current designs. Biasing avidity toward IL2Rα with an asymmetrical multivalent design consisting of one α/β chain–binding and one α chain–binding mutant further enhanced T reg selectivity. Comparative analysis revealed that IL2Rα was the optimal cell surface target for T reg selectivity, indicating that avidity for IL2Rα may be the optimal route to producing IL-2 variants that selectively target T regs .


  • Open Access

    Design of cell-type-specific hyperstable IL-4 mimetics via modular de novo scaffolds

    by Huilin Yang, Umut Y. Ulge, Alfredo Quijano-Rubio, Zachary J. Bernstein, David R. Maestas, Jung-Ho Chun, Wentao Wang, Jian-Xin Lin, Kevin M. Jude, Srujan Singh, et al.

    The interleukin-4 (IL-4) cytokine plays a critical role in modulating immune homeostasis. Although there is great interest in harnessing this cytokine as a therapeutic in natural or engineered formats, the clinical potential of native IL-4 is limited by its instability and pleiotropic actions. Here, we design IL-4 cytokine mimetics (denoted Neo-4) based on a de novo engineered IL-2 mimetic scaffold and demonstrate that these cytokines can recapitulate physiological functions of IL-4 in cellular and animal models. In contrast with natural IL-4, Neo-4 is hyperstable and signals exclusively through the type I IL-4 receptor complex, providing previously inaccessible insights into differential IL-4 signaling through type I versus type II receptors. Because of their hyperstability, our computationally designed mimetics can directly incorporate into sophisticated biomaterials that require heat processing, such as three-dimensional-printed scaffolds. Neo-4 should be broadly useful for interrogating IL-4 biology, and the design workflow will inform targeted cytokine therapeutic development.


  • A quantitative view of strategies to engineer cell-selective ligand binding

    by Zhixin Cyrillus Tan, Brian T Orcutt-Jahns, Aaron S Meyer

    A critical property of many therapies is their selective binding to target populations. Exceptional specificity can arise from high-affinity binding to surface targets expressed exclusively on target cell types. In many cases, however, therapeutic targets are only expressed at subtly different levels relative to off-target cells. More complex binding strategies have been developed to overcome this limitation, including multi-specific and multivalent molecules, creating a combinatorial explosion of design possibilities. Guiding strategies for developing cell-specific binding are critical to employ these tools. Here, we employ a uniquely general multivalent binding model to dissect multi-ligand and multi-receptor interactions. This model allows us to analyze and explore a series of mechanisms to engineer cell selectivity, including mixtures of molecules, affinity adjustments, valency changes, multi-specific molecules and ligand competition. Each of these strategies can optimize selectivity in distinct cases, leading to enhanced selectivity when employed together. The proposed model, therefore, provides a comprehensive toolkit for the model-driven design of selectively binding therapies.


  • Open Access

    Multivalent, asymmetric IL-2-Fc fusions provide optimally enhanced regulatory T cell selectivity

    by Brian Orcutt-Jahns, Peter C. Emmel, Eli M. Snyder, Cori Posner, Scott M. Carlson, Aaron S. Meyer, Scott D. Taylor

    The common γ-chain receptor cytokines coordinate the proliferation and function of immune cell populations. One of these cytokines, interleukin (IL)-2, has potential as a therapy in autoimmune disease but is limited in effectiveness by its modest specificity toward regulatory T cells (T reg s). Engineering T reg -selective IL-2 has primarily focused on retaining binding to the high-affinity receptor, expressed more highly on T reg s, while reducing binding to the lower affinity receptor with broader expression. However, other parameters, such as the orientation and valency of Fc fusion, have signaling effects that have never been systematically explored. Here, we systematically profiled the signaling responses to a panel of wild type and mutein IL-2-Fc fusions across time, cell types, and concentrations. Exploring these responses, we found that dimeric muteins have unique specificity for T reg s through binding avidity. A mechanistic model of receptor interactions could capture these effects and directed the design of tetravalent IL-2-Fc fusions with greater T reg specificity than possible with current design strategies. Exploration of other surface targets on T reg s revealed that there are no other binding moieties that could be fused to IL-2 for greater selectivity. Instead, IL2Rα itself is a maximally unique surface target for T reg s, and so avidity is likely the only route to more selective T reg interaction. However, the binding model revealed that asymmetrical, multivalent IL-2 fusions can bias avidity effects toward IL2Rα for even further enhanced T reg selectivity. These findings present a comprehensive analysis of how ligand properties and their effects on surface receptor-ligand interactions translate to selective activation of immune cell populations, and consequently reveals two new routes toward therapeutic cytokines with superior T reg selectivity that can be exploited for designing selective therapies in many other contexts. Significance Statement: Signaling in off-target immune cells has hindered the effectiveness of IL-2 as an immunotherapy. We show that IL-2-Fc fusions with higher valency can exhibit enhanced regulatory T cell selectivity. This altered selectivity is explained by the kinetics of surface receptor-ligand binding and can be quantitatively predicted using a multivalent binding model. Using these insights, we successfully develop two new strategies for IL-2 therapies with unprecedented selectivity. Highlights: Current IL-2 therapies are limited by a selectivity/target potency tradeoff. Multivalency enhances selectivity for T reg s through IL2Rα avidity. T reg selectivity cannot be enhanced by targeting other surface protein markers. Multivalency can decouple selectivity from signaling using asymmetric cytokine fusions.


  • Open Access

    A quantitative view of strategies to engineer cell-selective ligand binding

    by Zhixin Cyrillus Tan, Brian Orcutt-Jahns, Aaron S. Meyer

    A critical property of many therapies is their selective binding to specific target populations. Exceptional specificity can arise from high-affinity binding to unique cell surface targets. In many cases, however, therapeutic targets are only expressed at subtly different levels relative to off-target cells. More complex binding strategies have been developed to overcome this limitation, including multi-specific and multi-valent molecules, but these create a combinatorial explosion of design possibilities. Therefore, guiding strategies for developing cell-specific binding are critical to employ these tools. Here, we extend a multi-valent binding model to multi-ligand and multi-receptor interactions. Using this model, we explore a series of mechanisms to engineer cell selectivity, including mixtures of molecules, affinity adjustments, and valency changes. Each of these strategies maximizes selectivity in distinct cases, leading to synergistic improvements when used in combination. Finally, we identify situations in which selectivity cannot be derived through passive binding alone to highlight areas in need of new developments. In total, this work uses a quantitative model to unify a comprehensive set of design guidelines for engineering cell-specific therapies. Summary points Affinity, valency, and other alterations to target cell binding provide enhanced selectivity in specific situations. Evidence for the effectiveness and limitations of each strategy are abundant within the drug development literature. Combining strategies can offer enhanced selectivity. A simple, multivalent ligand-receptor binding model can help to direct therapeutic engineering.